In a post-hoc exploratory analysis of the KING trial to seek molecular markers of outcome, RNAseq was performed on resected tumor specimens at the time of diagnostic surgery before the recurrence from

NIAID Data Ecosystem30

Supplementary Table 2 from Attenuation of microRNA-126 Expression That Drives CD34+38− Stem/Progenitor Cells in Acute Myeloid Leukemia Leads to Tumor Eradication

肿瘤分子标志物

白血病研究

XLSX file - 14KB, MicroRNAs differentially expressed between LSC and progenitors (at least 4 out of 6 patients): Upper: MicroRNA expression ratios between CD34+CD38-ALDHlow/dim (LSC) and CD34+CD38+ALD

Figshare2014-04-01 更新10

PTEN homozygous deletion is a negative prognostic factor in Tumor Treating Fields-treated glioblastoma, IDH wildtype patients

胶质母细胞瘤预后

肿瘤分子标志物

PTEN homozygous deletion is a negative prognostic factor in Tumor Treating Fields-treated glioblastoma, IDH wildtype patients

ChEBI2025-12-04 更新30

Supplementary Table 3 from Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types

癌症基因组数据

肿瘤分子标志物

Genes differentially expressed in RB1 loss tumors with two or more RB1 mutations

NIAID Data Ecosystem20